Wedbush Starts Orchard Therapeutics (ORTX) at Outperform
- Nasdaq set for worst day in 2 months before big tech earnings
- Tesla (TSLA) Gains on Q2 Beat, Analysts Mostly Positive but Others Cautious
- China's Meituan (MPNGF) Plunges 17.6% to Push Hang Seng Index to 8-Month Lows as Heavy Selling Continues
- Raytheon (RTX) Gains on Beat-and-Raise, CEO Says Next War Will Be Fought in Cyber Space and Then Outer Space
- Dollar eases slightly with Fed in focus
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Wedbush analyst David Nierengarten initiates coverage on Orchard Therapeutics (NASDAQ: ORTX) with a Outperform rating and a price target of $25.00.
Shares of Orchard Therapeutics closed at $16.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Reinstates Crown Resorts Ltd (CWN:AU) (CWLDY) at Neutral
- JPMorgan Starts Minkabu The Infonoid Inc (4436:JP) at Overweight
- UPDATE: Bradesco BBI Assumes Itau Unibanco (ITUB) at Outperform
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!